Sequent Scientific Ltd. benchmarking: Perfomance to industry peers

Financial

	Sequent Scientific	Zota Health Care	Orchid Pharma
Operational Metrics
Pharmaceuticals
R&D as a % of Total Sales	0.0	0.09 %	n/a
Financials
5 yr Average ROE	-0.13 %	-7.74 %	0.86 %
5yr average Equity Multiplier	2.16	1.84	1.61
5yr Average Asset Turnover Ratio	0.95	0.91	0.5
5yr Avg Net Profit Margin	0.03 %	-4.95 %	0.56 %
Price to Book	6.28	15.47	3.32
P/E	121.51	0.0	80.96
5yr Avg Cash Conversion Cycle	49.09 Days	40.5 Days	52.03 Days
Inventory Days	80.25 Days	91.82 Days	112.47 Days
Days Receivable	79.76 Days	42.2 Days	86.58 Days
Days Payable	114.46 Days	92.36 Days	159.29 Days
5yr Average Interest Coverage Ratio	1.93	5.98	3.01
5yr Avg ROCE	6.67 %	-2.72 %	3.08 %
5yr Avg Operating Profit Margin	7.74 %	3.69 %	11.84 %
5 yr average Debt to Equity	0.53	0.04	0.37
5yr CAGR Net Profit	-25.52 %	206.06 %	n/a
5yr Average Return on Assets	0.05 %	-3.4 %	1.2 %
Shareholdings
Promoter Holding	52.33 %	55.81 %	69.84 %
Share Pledged by Promoters	0.0	0.26 %	0.0
Change in Promoter Holding (3 Yrs)	-0.46 %	-12.31 %	-20.12 %
Change in Mutual Fund Holding (3 Yrs)	9.59 %	0.06 %	15.59 %

Business

	Sequent Scientific	Zota Health Care	Orchid Pharma
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0	-	-
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0	-	-
Product Wise Break-Up	Product Wise Break-Up Formulations 79.96 Active Pharmaceutical Ingredient (API) 19.73 Retail Pharmacy 0 Export 0 0 Sterile 0 Oral Formulations 0 Others 0.31	Product Wise Break-Up Formulations 0 Sterile 0 Export 10.89 Active Pharmaceutical Ingredient (API) 0 Pharmacy 63.56 Marketing 21.65 Oral Formulations 0 Others 3.9	Product Wise Break-Up Formulations 0 Sterile 27.56 Export 0 Active Pharmaceutical Ingredient (API) 0 Retail Pharmacy 0 0 Oral Formulations 72.44
Location Wise Break-Up	Location Wise Break-Up Europe 45.13 Asia Pacific 28.68 Rest of the World 26.19 Turkey 0 LATAM 0 EM 0 India 0	Location Wise Break-Up LATAM 0 Asia Pacific 0 Europe 0 Rest of the World 8.0 India 92.0 Turkey 0 EM 0	Location Wise Break-Up LATAM 0 Asia Pacific 0 Europe 0 Rest of the World 0 India 19.9 Turkey 0 EM 0 Others 80.1
Customer Segment	Customer Segment Regulated market 67.0 Less regulated market 33.0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Antibiotic Injectables 33.0 Antibiotic Non-Injectables 15.0 Anthelmintics 11.0 Nutritional 0 Pain management 0 Others 41.0	-	-
R&D Break-Up - Product Wise	R&D Break-Up - Product Wise Formulations 40.0 NiCad 29.0 Patent expiry opportunity 18.0 First generic 9.0 Incremental innovation 4.0	-	-
Dosage Form Break-Up	Dosage Form Break-Up Injectable 55.0 Powder/Premixes 26.0 Solid 6.0 Paste and others 0 Pour on/Spot on 0 Oral Solutions/Suspensions 0 Others 13.0	-	-
Asset Break-Up	Asset Break-Up Asia Pacific 43.23 Europe 34.35 Rest of the World 22.42	-	-
Species Break-Up	Species Break-Up Multispecies 39.0 Ruminants 32.0 Poultry And Poultry Products 12.0 Companion 10.0 Swine 6.0 Others 1.0	-	-

Sequent Scientific Ltd.

Sequent Scientific Ltd.

Financial

Business

SIGN UP FOR FREE